OSTEOARTHRITIS AND ISCHEMIC HEART DISEASE: THE MODERN ASPECTS OF INFLUENCE AND TREATMENT
Keywords:
CAD, osteoarthritis, treatmentAbstract
Osteoarthritis is the most prevalent form of arthritis, with an associated risk of mobility disability (defined as needing help walking or climbing stairs) for those with affected knees being greater than that due to any other medical condition in people aged 65. The societal burden (both in terms of personal suffering and use of health resources) is expected to increase with the increasing prevalence of obesity and the ageing of the community. Osteoarthritis is a multifactorial process in which mechanical factors have a central role and is characterised by changes in structure and function of the whole joint. The problems of biinfluence of CAD and osteoarthritis, effects of NSAIDs on heart and statins on joints were discussed.
References
1. Современные генетические аспекты атеросклероза: Обзор литературы / Е.А.Дегтярева, Е.В.Тозлиян, Л.З.Казанцева, Г.Г.Осокина // Междун. Мед. Журн. – 2000. – №1. – С. 80-88.
2. Москалевич Б. Ревматические заболевания – проблема, недооцениваемая общественным здравоохранением в Польше // Научно–практическая ревматология. – 2001. – №1. – С. 11–15.
3. Насонов Е.Л. Применение нестероидных противовоспалительных препаратов в медицине в начале 21 века // РМЖ. – 2003. – №11. – С. 375-378.
4. Насонов Е.Л. Специфические ингибиторы ЦОГ–2: решенные и нерешенные проблемы // Клин. Фармакология и терапія. – 2000. – №1. – С. 60-64.
5. Насонова В., Бунчук Н.В. Ревматические болезни: Руководство для врачей. Москва: Медицина. – 1997. – 520 с.
6. Стан здоров’я населення України та забезпечення надання медичної допомоги / За редакцією Гайдаєва Ю.О. – Київ, 2007. – 98 с.
7. Шевченко О.П., Шевченко А.О. Статины. Ингибиторы ГМГ–КоА редуктазы. – Москва, 2002. – 112 с.
8. Saito T, Rodger IW, Hu E. et al. Inhibition of cyclooxygenase–2 improves cardiac function in myocardial infarction // Biochem Biophys Res Commun. – 2000. – Р. 772-775.
9. Baigent C, Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease. A reappraisal // Arthritis Rheum. – 2003. – 48. – Р.12-20.
10. Baker CS, Hall RJ, Evans TJ et al. Cyclooxygenase 2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalized with inducible nitric oxide synthase and nitrotyrosine particularly macrophages // Atheroscler Thromb Vasc Biol. – 1999. – 19. – Р. 646-655.
11. Belton O, Byrne D, Kearney D. et al. Cyclooxygenase–1 and – 2 dependent prostacyclin formation in patients with atherosclerosis // Circulation. – 2000. – 102. – Р. 840-845.
12. Bombardier C, Lane L, Reicin A. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis // New Engl J Med. – 2000. – 343. – Р. 1520-1528.
13. Burleigh ME, Babaev VR, Oates JA. et al. Cyclooxygenase –2 promotes early atherosclerotic lesion formation in LDL receptor deficiency mice // Circulation. – 2002. – 105. – Р. 1816-1823.
14. Chenevard R., Hurlimann D., Bechir M. et al. Selective COX–2 inhibition improves endothelial function in coronary artery disease // Circulation. – 2003. – Р. 107.
15. Cheng Y, Austin SC, Rocca B. et al. Role of prostacyclin in the cardiovascular response to thromboxane A2 // Science. – 2002. – 296. – Р. 539-541.
16. Cippilone F, Prontera C., Pini B. et al. Overexpression of functionally coupled cyclooxygenase E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E2–dependent plaque instability // Circulation. – 2001. – 104. – Р. 921-930.
17. Crofford LJ, Oates JC, McCune WI et al. Thrombosis in patients with connective tissue disease treated with specific cycloxygenase–2 inhibitors: a report of four cases // Arthritis Rheum. – 2000. – 3. – Р. 1891-1896.
18. Dieppe PA, Lohmander LS. Pathogenesis and management of pain in osteoarthritis // Lancet. – 2005. – 365. – Р. 965-973.
19. Felson D.T., Lawrence R.C., Dieppe P.A. et al. Osteoarthritis: new insights, part 16 the disease and its risk factors // Ann. Intern. Med. – 2000. – 133. – Р. 635-646.
20. Ferrara D, Liu X, Espinola RG. et al. Effects of fluvastatin on inflammatory and thrombogenic properties of antiphospholipid antibodies in vivo // ACR. – 2002. – Р. 504.
21. FitzGerald GA, Patrono C. The Coxibs, selective inhibitors of cyclooxygenase–2 // New Engl J Med. – 2001. – 345. – Р. 433-442.
22. Frenette PS. Lockin a leukocyte integrin with stastin // New Engl J Med. – 2001. – 345. – Р. 1419-1421.
23. Garcia Rodriguez LA. The effect of NSAIDs on the risk of coronary heart disease: fusion of clinical pharmacology and pharmacoepidemilogic data // Clin Exp. Rheumatol. – 2001. – 19 (suppl. 25). – Р. 41-45.
24. Greenberg H, Gottesdiener K, Huntington M, et al. A new cyclooxygenase–2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low–dose aspirin in healthy volunteers // J Clin Pharm. – 2000. – 40. – Р. 1509-1515.
25. Grip O, Janciauskiene S, Lindgren S. Pravastatin down–regulates inflammatory mediators in human monocytes in vitro // Eur J Pharmacol. – 2000. – 410. – Р. 83-92.
26. Hennan JK, Huang J, Barrett TD, et al. Effects of selective cyclooxygenase–2 inhibition on vascular response and thrombosis in canine arteries // Circulation. – 2001. – 104. – Р. 820-825.
27. Hudson M, Baron M, Rahme E, Pilot L. Anti–inflammatory drugs with a decrease risk of recurrent acute myocardial infarction in patients on aspirin // ACR 66th Annual Scientific Meeting. – New Orleans, 2002. – Р. 16-63.
28. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT) // Ann Rheum Dis. – 2003. – 62. – Р. 45-55.
29. Kessenich, C. R. Review: topical NSAIDs reduce pain in osteoarthritis only during the first 2 weeks of use // Evid. Based Nurs. – 2005. – 8. – Р. 20-20.
30. Kim SY, Guijarro C, O’Donnell MP, Kasiske BL, Kim Y, Keane WF: Human mesangial cell production of monocyte chemoattractant protein–1: modulation by lovastatin // Kidney Int. – 1995. – 48. – Р. 63-71.
31. Ko D., Wang Y, Berger AK et al. Nonsteroidal anti–inflammatory drugs after acute myocardial infarction // Am Heart J. – 2002. – 143. – Р. 475-481.
32. Konstam MA, Weir AR. Current persective on the cardiovascular effects of coxibs // Clev Clin J Med 2002. – Suppl 1. – SI–47–SI–52.
33. Layton D, Hughes K, Harris S, Shakir SAW. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescribtion-Events Monitoring (PEM) data // Rheumatology. – 2003. – 42. – Р. 1-11.
34. Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H, Madhok R, Campbel C, Gracie JA, Liew FY, McInnes IB. A novel anti–inflammatory tole for simvastatin in inflammatory atthritis // J Immunol. – 2003. – 170. – Р. 1524-1530.
35. Marcus AJ, Broekman MJ, Pinsky GJ. COX inhibition and thromboregulation // N Engl J Med. – 2002. – 347. – Р. 1025-1026.
36. McAdam BF, Catella–Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)–2: the human pharmacology of a selective inhibitors of COX–2 // PNAS. – 1999. – 96. – Р. 272-277.
37. Meroni PL, Raschi E, Testoni C., et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti– beta2–glycoprotein 1) antibodies. Effect on the proadhesive and prounflammatory phenotype // Arthritis Rheum. – 2001. – 44. – Р. 2870-2878.
38. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX–2 inhibitors // JAMA. – 2001. – 286. – Р. 954-959.
39. Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A: Anti–inflammatory effects of simvastatin in subjects with hypercholesterolemia // Int J Cardiol. – 2001. – 77. – Р. 247-53.
40. Ouellett M, Riendeau D, Percival D. A high level of cyclooxygenase–2 inhibitor selectivity is associated with a reduced intereference of platelet cyclooxygenase–1 inactivation by aspirin // PNAS 2001. – 98. – Р. 14583–14588.
41. Ray WA, Stein CM, Hall K., et al. Non–steroidal anti–inflammatory drugs and risk of serious coronary heart disease: an observational cohort study // Lancet. – 2002. – 359. – Р. 118-123.
42. Reicin AS, Shapiro D, Sperlong RS et al. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti–inflammatory druds (ibuprofen, diclofenac and nabumeton) // Am Cardiol. – 2002. – 89. – Р. 204-209.
43. Romano M, Diomede L, Sironi M et al: Inhibition of monocyte chemotactic protein–1 synthesis by statins // Lab Invest. – 2000. – 80. – Р. 95-100.
44. Rosenson RS, Tangney CC, Casey LC: Inhibition of proinflammatory cytokine production by pravastatin // Lancet. – 1999. – 353. – Р. 983-984.
45. Schitcer T.J., Burmester G.R., Mysler E. et al. Comparison of lumiracoxib with naproxen and ibuprofen in the TARGET, reduction of ulcer complications: randomized controlled trial // Lancet. – 2004. – 364. – P. 665-674.
46. Schonbeck U, Sukhova GK, Graber P, et al. Augmented expression of cyclooxigenase–2 in human atherosclerotic lesions // Am J Pathol. – 1999. – 155. – Р. 1281-1291.
47. Strand V, Hochberg MC. The risk of cardiovascular thrombotic events with selective cyclooxygenase–2 inhibitors // Arthritis Rheum (Arthritis Care&Res). – 2002. – 47. – Р. 349-355.
48. Van Solingen R.M., Rosenstein E.D., Mihailescu G., et al. Comparison of the effects of ketoprofen on platelet function in the presence and absence of aspirin //Am. J. Med. – 2001. – 111. – Р. 285-289.
49. Weber C, Erl W, Weber KS, Weber PC: HMG–CoA reductase inhibitors decrease CD11b expression and CD11b–dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes to endothelium and reduce increased adhevsiveness of monocytes isolated from patients with hypercholesterinemia // J Am Col Cardiol. – 1997. – 30. – Р. 1212-1227.
50. Weitz–Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen–1 by binding to a novel regulatory integrin site // Nat Med. – 2001. – 7. – Р. 687-692.
51. White WB, Faich G, Borer JS, Makuch R. Cardiovascular thrombotic events are not increased on the cyclooxygenase–2 inhibitor – celecoxib // ACR 66th Annual Scientific Meeting. – New Orleans, 2002. – Р. 485.
52. White WB., Faich G., Whelton A. et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase–2 specific inhibitor, versus ibuprofen or diclofenac // Am J Cardiol. – 2002. – 89. – Р. 425-430.
2. Москалевич Б. Ревматические заболевания – проблема, недооцениваемая общественным здравоохранением в Польше // Научно–практическая ревматология. – 2001. – №1. – С. 11–15.
3. Насонов Е.Л. Применение нестероидных противовоспалительных препаратов в медицине в начале 21 века // РМЖ. – 2003. – №11. – С. 375-378.
4. Насонов Е.Л. Специфические ингибиторы ЦОГ–2: решенные и нерешенные проблемы // Клин. Фармакология и терапія. – 2000. – №1. – С. 60-64.
5. Насонова В., Бунчук Н.В. Ревматические болезни: Руководство для врачей. Москва: Медицина. – 1997. – 520 с.
6. Стан здоров’я населення України та забезпечення надання медичної допомоги / За редакцією Гайдаєва Ю.О. – Київ, 2007. – 98 с.
7. Шевченко О.П., Шевченко А.О. Статины. Ингибиторы ГМГ–КоА редуктазы. – Москва, 2002. – 112 с.
8. Saito T, Rodger IW, Hu E. et al. Inhibition of cyclooxygenase–2 improves cardiac function in myocardial infarction // Biochem Biophys Res Commun. – 2000. – Р. 772-775.
9. Baigent C, Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease. A reappraisal // Arthritis Rheum. – 2003. – 48. – Р.12-20.
10. Baker CS, Hall RJ, Evans TJ et al. Cyclooxygenase 2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalized with inducible nitric oxide synthase and nitrotyrosine particularly macrophages // Atheroscler Thromb Vasc Biol. – 1999. – 19. – Р. 646-655.
11. Belton O, Byrne D, Kearney D. et al. Cyclooxygenase–1 and – 2 dependent prostacyclin formation in patients with atherosclerosis // Circulation. – 2000. – 102. – Р. 840-845.
12. Bombardier C, Lane L, Reicin A. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis // New Engl J Med. – 2000. – 343. – Р. 1520-1528.
13. Burleigh ME, Babaev VR, Oates JA. et al. Cyclooxygenase –2 promotes early atherosclerotic lesion formation in LDL receptor deficiency mice // Circulation. – 2002. – 105. – Р. 1816-1823.
14. Chenevard R., Hurlimann D., Bechir M. et al. Selective COX–2 inhibition improves endothelial function in coronary artery disease // Circulation. – 2003. – Р. 107.
15. Cheng Y, Austin SC, Rocca B. et al. Role of prostacyclin in the cardiovascular response to thromboxane A2 // Science. – 2002. – 296. – Р. 539-541.
16. Cippilone F, Prontera C., Pini B. et al. Overexpression of functionally coupled cyclooxygenase E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E2–dependent plaque instability // Circulation. – 2001. – 104. – Р. 921-930.
17. Crofford LJ, Oates JC, McCune WI et al. Thrombosis in patients with connective tissue disease treated with specific cycloxygenase–2 inhibitors: a report of four cases // Arthritis Rheum. – 2000. – 3. – Р. 1891-1896.
18. Dieppe PA, Lohmander LS. Pathogenesis and management of pain in osteoarthritis // Lancet. – 2005. – 365. – Р. 965-973.
19. Felson D.T., Lawrence R.C., Dieppe P.A. et al. Osteoarthritis: new insights, part 16 the disease and its risk factors // Ann. Intern. Med. – 2000. – 133. – Р. 635-646.
20. Ferrara D, Liu X, Espinola RG. et al. Effects of fluvastatin on inflammatory and thrombogenic properties of antiphospholipid antibodies in vivo // ACR. – 2002. – Р. 504.
21. FitzGerald GA, Patrono C. The Coxibs, selective inhibitors of cyclooxygenase–2 // New Engl J Med. – 2001. – 345. – Р. 433-442.
22. Frenette PS. Lockin a leukocyte integrin with stastin // New Engl J Med. – 2001. – 345. – Р. 1419-1421.
23. Garcia Rodriguez LA. The effect of NSAIDs on the risk of coronary heart disease: fusion of clinical pharmacology and pharmacoepidemilogic data // Clin Exp. Rheumatol. – 2001. – 19 (suppl. 25). – Р. 41-45.
24. Greenberg H, Gottesdiener K, Huntington M, et al. A new cyclooxygenase–2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low–dose aspirin in healthy volunteers // J Clin Pharm. – 2000. – 40. – Р. 1509-1515.
25. Grip O, Janciauskiene S, Lindgren S. Pravastatin down–regulates inflammatory mediators in human monocytes in vitro // Eur J Pharmacol. – 2000. – 410. – Р. 83-92.
26. Hennan JK, Huang J, Barrett TD, et al. Effects of selective cyclooxygenase–2 inhibition on vascular response and thrombosis in canine arteries // Circulation. – 2001. – 104. – Р. 820-825.
27. Hudson M, Baron M, Rahme E, Pilot L. Anti–inflammatory drugs with a decrease risk of recurrent acute myocardial infarction in patients on aspirin // ACR 66th Annual Scientific Meeting. – New Orleans, 2002. – Р. 16-63.
28. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT) // Ann Rheum Dis. – 2003. – 62. – Р. 45-55.
29. Kessenich, C. R. Review: topical NSAIDs reduce pain in osteoarthritis only during the first 2 weeks of use // Evid. Based Nurs. – 2005. – 8. – Р. 20-20.
30. Kim SY, Guijarro C, O’Donnell MP, Kasiske BL, Kim Y, Keane WF: Human mesangial cell production of monocyte chemoattractant protein–1: modulation by lovastatin // Kidney Int. – 1995. – 48. – Р. 63-71.
31. Ko D., Wang Y, Berger AK et al. Nonsteroidal anti–inflammatory drugs after acute myocardial infarction // Am Heart J. – 2002. – 143. – Р. 475-481.
32. Konstam MA, Weir AR. Current persective on the cardiovascular effects of coxibs // Clev Clin J Med 2002. – Suppl 1. – SI–47–SI–52.
33. Layton D, Hughes K, Harris S, Shakir SAW. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescribtion-Events Monitoring (PEM) data // Rheumatology. – 2003. – 42. – Р. 1-11.
34. Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H, Madhok R, Campbel C, Gracie JA, Liew FY, McInnes IB. A novel anti–inflammatory tole for simvastatin in inflammatory atthritis // J Immunol. – 2003. – 170. – Р. 1524-1530.
35. Marcus AJ, Broekman MJ, Pinsky GJ. COX inhibition and thromboregulation // N Engl J Med. – 2002. – 347. – Р. 1025-1026.
36. McAdam BF, Catella–Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)–2: the human pharmacology of a selective inhibitors of COX–2 // PNAS. – 1999. – 96. – Р. 272-277.
37. Meroni PL, Raschi E, Testoni C., et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti– beta2–glycoprotein 1) antibodies. Effect on the proadhesive and prounflammatory phenotype // Arthritis Rheum. – 2001. – 44. – Р. 2870-2878.
38. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX–2 inhibitors // JAMA. – 2001. – 286. – Р. 954-959.
39. Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A: Anti–inflammatory effects of simvastatin in subjects with hypercholesterolemia // Int J Cardiol. – 2001. – 77. – Р. 247-53.
40. Ouellett M, Riendeau D, Percival D. A high level of cyclooxygenase–2 inhibitor selectivity is associated with a reduced intereference of platelet cyclooxygenase–1 inactivation by aspirin // PNAS 2001. – 98. – Р. 14583–14588.
41. Ray WA, Stein CM, Hall K., et al. Non–steroidal anti–inflammatory drugs and risk of serious coronary heart disease: an observational cohort study // Lancet. – 2002. – 359. – Р. 118-123.
42. Reicin AS, Shapiro D, Sperlong RS et al. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti–inflammatory druds (ibuprofen, diclofenac and nabumeton) // Am Cardiol. – 2002. – 89. – Р. 204-209.
43. Romano M, Diomede L, Sironi M et al: Inhibition of monocyte chemotactic protein–1 synthesis by statins // Lab Invest. – 2000. – 80. – Р. 95-100.
44. Rosenson RS, Tangney CC, Casey LC: Inhibition of proinflammatory cytokine production by pravastatin // Lancet. – 1999. – 353. – Р. 983-984.
45. Schitcer T.J., Burmester G.R., Mysler E. et al. Comparison of lumiracoxib with naproxen and ibuprofen in the TARGET, reduction of ulcer complications: randomized controlled trial // Lancet. – 2004. – 364. – P. 665-674.
46. Schonbeck U, Sukhova GK, Graber P, et al. Augmented expression of cyclooxigenase–2 in human atherosclerotic lesions // Am J Pathol. – 1999. – 155. – Р. 1281-1291.
47. Strand V, Hochberg MC. The risk of cardiovascular thrombotic events with selective cyclooxygenase–2 inhibitors // Arthritis Rheum (Arthritis Care&Res). – 2002. – 47. – Р. 349-355.
48. Van Solingen R.M., Rosenstein E.D., Mihailescu G., et al. Comparison of the effects of ketoprofen on platelet function in the presence and absence of aspirin //Am. J. Med. – 2001. – 111. – Р. 285-289.
49. Weber C, Erl W, Weber KS, Weber PC: HMG–CoA reductase inhibitors decrease CD11b expression and CD11b–dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes to endothelium and reduce increased adhevsiveness of monocytes isolated from patients with hypercholesterinemia // J Am Col Cardiol. – 1997. – 30. – Р. 1212-1227.
50. Weitz–Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen–1 by binding to a novel regulatory integrin site // Nat Med. – 2001. – 7. – Р. 687-692.
51. White WB, Faich G, Borer JS, Makuch R. Cardiovascular thrombotic events are not increased on the cyclooxygenase–2 inhibitor – celecoxib // ACR 66th Annual Scientific Meeting. – New Orleans, 2002. – Р. 485.
52. White WB., Faich G., Whelton A. et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase–2 specific inhibitor, versus ibuprofen or diclofenac // Am J Cardiol. – 2002. – 89. – Р. 425-430.
Downloads
Published
2019-10-09
How to Cite
Глушко, Л. В. ., Федоров, С. В. ., & Адед, І. . (2019). OSTEOARTHRITIS AND ISCHEMIC HEART DISEASE: THE MODERN ASPECTS OF INFLUENCE AND TREATMENT. PRECARPATHIAN BULLETIN OF THE SHEVCHENKO SCIENTIFIC SOCIETY Pulse, (4(4), 50–59. Retrieved from https://pvntsh.nung.edu.ua/index.php/pulse/article/view/929
Issue
Section
КЛІНІЧНА МЕДИЦИНА
